Share on StockTwits

RBC Capital started coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note issued on Friday. The firm set an “outperform” rating on the stock.

Gilead Sciences (NASDAQ:GILD) opened at 96.36 on Friday. Gilead Sciences has a one year low of $56.25 and a one year high of $96.37. The stock has a 50-day moving average of $89.64 and a 200-day moving average of $81.09. The company has a market cap of $145.7 billion and a P/E ratio of 21.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, July 23rd. The company reported $2.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.73 by $0.63. The company had revenue of $6.53 billion for the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the previous year, the company posted $0.50 earnings per share. The company’s revenue for the quarter was up 136.1% on a year-over-year basis. Analysts expect that Gilead Sciences will post $8.02 EPS for the current fiscal year.

GILD has been the subject of a number of other recent research reports. Analysts at FBR Capital Markets initiated coverage on shares of Gilead Sciences in a research note on Thursday. They set an “outperform” rating and a $125.00 price target on the stock. Separately, analysts at Argus initiated coverage on shares of Gilead Sciences in a research note on Monday. They set a “buy” rating and a $110.00 price target on the stock. Finally, analysts at Zacks upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating in a research note on Thursday, August 7th. They now have a $111.00 price target on the stock. One analyst has rated the stock with a hold rating and twenty have given a buy rating to the stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $104.53.

In other Gilead Sciences news, Director Richard James Whitley sold 5,000 shares of the stock on the open market in a transaction dated Friday, August 1st. The shares were sold at an average price of $91.00, for a total value of $455,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Gilead Sciences, Inc (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops and commercializes medicines.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.